Navigation Links
AstraZeneca Response to February 21, 2008 Ruling In Re: Alabama Medicaid Pharmaceutical AWP Litigation - cv2005-219 - Circuit Court of Montgomery, Alabama
Date:2/21/2008

WILMINGTON, Del., Feb. 21 /PRNewswire-FirstCall/ -- AstraZeneca believes this lawsuit is legally and factually unfounded and we intend to appeal to the Alabama Supreme Court, if the trial court does not reject the jury's verdict. The case was based on the misleading premise that the Alabama State Medicaid Agency did not understand the basics on how drug prices are established and reported.

We believe numerous errors occurred during the proceedings and that the verdict should not be upheld.

For example, the Court ruled that important information on the workings of the Alabama pharmacy system be withheld throughout the trial. The Court also permitted evidence of earlier, unrelated settlements and proceedings in clear violation of the rules of evidence. These and other reversible errors were compounded by negative public comments by the trial lawyers and state leaders prior to the jury selection process.

AstraZeneca has fully complied with the law, government guidelines and contracts that govern Medicaid pricing. We currently provide medicines to Medicaid programs at the lowest price that we offer to our best business clients, as federal law requires.

AstraZeneca and the State Medicaid program share a common goal of helping people access the medicines they need.

To help patients who have difficulty affording their medicines, we offer patient assistance programs side by side with our medicines. In the last two years alone, AstraZeneca helped more than 28,800 Alabama patients receive more than $25.5 million in savings through its prescription savings programs.


'/>"/>
SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
2. Epistem plc and AstraZeneca Complete Plucked Hair Biomarker Study for Oncology Drug Development
3. AstraZeneca and Banner Alzheimers Institute Collaborate to Evaluate New Tool Targeting Alzheimers Disease
4. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
5. Pediatric Asthma Programs Featuring PARI Pharmas eFlow Acquired by AstraZeneca
6. Solstice Neurosciences, Inc. Issues Corporate Response to FDA Early Communication
7. Statement by John Bailey, Chief Scientist: The Personal Care Products Council Response to Study on Phthalate Exposure in Baby Care Products
8. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
9. CNS Response, Inc Completes Neuro-Therapy Clinic Acquisition; Names Daniel A. Hoffman, MD Chief Medical Officer
10. Triage study challenges notions of emergency medical response to disaster
11. CNS Response, Inc. Announces Acquisition of Neuropsychiatric Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... -- Neogen Corporation (NASDAQ: NEOG ) announced ... as its chief science officer — a new position ... Neogen effective Jan. 1. Kephart has served ... of Thermo Fisher Scientific, as well as animal health ... industry experience also includes the management of a team ...
(Date:12/7/2016)... , Dec. 7, 2016  Nordion, a ... General Atomics (GA), welcome today,s award by the ... Security Administration (NNSA) of the Phase II cooperative ... with Nordion and the University of Missouri Research ... funding will support the establishment of a new, ...
(Date:12/7/2016)... , Dec. 7, 2016  Vyriad Inc. announced today ... the company,s Board of Directors. "We are ... build our business and develop our oncolytic viruses as ... said Stephen Russell , MD, PhD, CEO of ... share our vision and passion for making a difference ...
(Date:12/7/2016)... YORK and ANN ARBOR, Mich. ... privately held biopharmaceutical company developing breakthrough immune modulatory medicines, ... trial of the Company,s lead therapeutic candidate, LYC-30937- E ... is often a debilitating skin disease that is estimated ... the United States , with approximately 1.5 ...
Breaking Biology Technology:
(Date:11/22/2016)... November 22, 2016 According to the new market ... Print, Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact ... MarketsandMarkets, the market is expected to grow from USD 10.74 Billion in ... 16.79% between 2016 and 2022. Continue Reading ... ...
(Date:11/17/2016)... CITY OF INDUSTRY, Calif. , Nov. 17, 2016  AIC announces that it ... about using NVMe storage servers in organizations that require high-performance scale-out plus high speed data transfer ... ... ... Setting ...
(Date:11/14/2016)... , Nov. 14, 2016  Based on ... market, Frost & Sullivan recognizes FST Biometrics ... Award for Visionary Innovation Leadership. FST Biometrics ... biometric identification market by pioneering In Motion ... for instant, seamless, and non-invasive verification. This ...
Breaking Biology News(10 mins):